Ivosidenib is a small-molecular inhibitor of mutant IDH1 which has been shown to be mutated in various cancers such as colorectal cancer, prostate tumors, melanomas, leukemias, and cholangiocarcinoma [63,64]. This evidence concerns the gene IDH1 and cholangiocarcinoma.